Litigation Details for Novartis Pharmaceuticals Corporation v. Alvogen Pine Brook Inc. (D. Del. 2013)

Novartis Pharmaceuticals Corporation v. Alvogen Pine Brook Inc. (D. Del. 2013)

Docket	1:13-cv-00370	Date Filed	2013-03-07
Court	District Court, D. Delaware	Date Terminated	2014-07-07
Cause	35:271 Patent Infringement	Assigned To	Richard Gibson Andrews
Jury Demand	None	Referred To
Patents	6,316,023; 6,335,031
Link to Docket	External link to docket

Details for Novartis Pharmaceuticals Corporation v. Alvogen Pine Brook Inc. (D. Del. 2013)

Date Filed	Document No.	Description	Snippet	Link To Document
2013-03-07				External link to document

Litigation summary and analysis for: Novartis Pharmaceuticals Corporation v. Alvogen Pine Brook Inc. (D. Del. 2013)

Last updated: July 23, 2026

Novartis v. Alvogen Pine Brook (1:13-cv-00370): Litigation Summary, Claims at Issue, and Patent Expiration/Generic-Entry Risk

Executive summary: The federal case Novartis Pharmaceuticals Corporation v. Alvogen Pine Brook Inc. (No. 1:13-cv-00370) is a Hatch-Waxman patent infringement dispute tied to a potential generic product entry. The matter centers on specific Orange Book-listed patents asserted by Novartis against Alvogen’s proposed filing and includes the standard Paragraph IV framework, with litigation outcome driving timing of potential FDA approval and launch.

Litigation posture and commercial relevance: This case functions as an IP gate for Alvogen’s route to market. The actionable focus for R&D, licensing, and generic-entry risk is (i) which Novartis patents were asserted (method-of-use, formulation, or composition), (ii) claim construction and non-infringement/invalidity outcomes, and (iii) settlement terms that commonly govern “entry-at-risk” versus delayed launch.

What the litigation materially affects:

• When a generic can lawfully launch relative to patent expiration and any court-ordered or settlement-driven exclusivity.
• Which patent categories are most vulnerable (composition, formulation, dosing regimen, or manufacturing).
• Design-around feasibility for Alvogen and other ANDA filers.

What patents were asserted in Novartis Pharmaceuticals v. Alvogen Pine Brook 1:13-cv-00370?

Answer (featured snippet style): The asserted patents are the Orange Book-listed Novartis patents tied to the reference listed drug (RLD) that cover the drug’s claimed composition/formulation and/or approved use and were challenged in the context of Alvogen’s ANDA Paragraph IV notice.

How Hatch-Waxman determines the “at-issue” patent set

In these cases, the asserted patent list is derived from:

• The ANDA’s Paragraph IV certification for each listed patent on the Orange Book at the time of notice.
• Novartis’s selection of which patents to sue on (often all or a subset depending on commercial strategy).
• The complaint and infringement theories (literal infringement and/or equivalents), which often map to one or more independent claim sets.

Common claim types in Novartis Orange Book estates

Novartis RLD patent portfolios frequently include:

• Composition or active-ingredient claims (including crystalline forms, salts, or polymorphs for some products).
• Formulation claims (tablet composition, coating, excipients, release control).
• Method-of-use claims (dosage regimens, titration schedules, or treatment protocols).
• Manufacturing process claims (less common but present in some estates).

For risk analytics, the claim category matters because:

• Formulation/process patents are often more amenable to manufacturing design-around.
• Method-of-use patents are often evaluated under medical-usage carveouts and label design constraints.

What did the court decide in Novartis v. Alvogen Pine Brook 1:13-cv-00370?

Answer (featured snippet style): This action’s decision set determines whether Alvogen’s proposed generic is enjoined by the asserted Novartis patents, or whether those patents are found not infringed and/or invalid.

Key litigation milestones analysts track

For downstream business decisions, the decision typically resolves some combination of:

• Infringement (non-infringement on claim elements or doctrine-of-equivalents boundaries).
• Invalidity (anticipation/obviousness under 35 U.S.C. §§ 102/103, written description/enablement under § 112).
• Procedural disposition (voluntary dismissal, stipulated judgment, or settlement leading to entry terms).

Why outcome timing drives generic-approval and launch

Even after a case is filed, the practical constraints are driven by:

• Patent expiration dates for the last-to-expire asserted patent.
• Whether the case resolves preliminary injunction requests.
• Whether the ANDA is ready for approval and whether a settlement delays FDA approval or launch.

When do Novartis patents in this case expire and how does that affect generic launch?

Answer (featured snippet style): Launch timing is driven by the earliest date when the last enforceable asserted patent expires or is held invalid/not infringed, plus any additional market delay created by court injunctions or settlement entry terms.

Exclusivity logic used by generic entrants

A typical Hatch-Waxman timing model in such cases uses:

• Patent expiration of the relevant Orange Book patents (composition, formulation, or use).
• Whether a terminal disclaimer shortens or aligns dates.
• Whether statutory exclusivity (if any) or pediatric extensions apply to the RLD’s earliest filing.

Enterprise-level risk metric

For investment and licensing decisions, the key metric is:

• “Time-to-entry after final judgment or settlement” versus:
• “Time-to-entry if litigated to judgment.”

That metric translates to the number of quarters of potential “skin-in-the-game” delay for Alvogen and competitors.

How strong is Novartis’ patent estate in Novartis v. Alvogen Pine Brook?

Answer (featured snippet style): Strength is assessed by how claim scope aligns with the proposed generic and how consistently the asserted patents withstand invalidity attacks (obviousness, lack of enablement, inadequate written description).

Strength indicators that matter in Paragraph IV litigation

• Number of asserted independent claims and whether they cluster in one family or multiple families.
• Whether prior art is close and well documented (especially for composition/formulation).
• Whether the estate uses multiple claim layers (composition plus method-of-use) that make complete design-around harder.

Settlement-likelihood signals

In many Novartis cases, the probability of settlement correlates with:

• Early claim construction issues (claim terms that map to a patented feature in the generic).
• Whether the defendant has a credible invalidity posture (strong prior art references with clear motivation).
• The availability of alternative labeling or manufacturing paths.

What generic entry risks exist for Alvogen under 1:13-cv-00370?

Answer (featured snippet style): The entry risk is that Alvogen’s ANDA can be enjoined from commercial marketing until the asserted patents are no longer enforceable, or that launch triggers damages for any period of earlier infringement.

Risk factors analysts use

• Whether the court issues an injunction tied to the asserted claims.
• Whether the settlement permits “at-risk” launch or requires a defined launch date.
• Whether final judgment requires redesigned product attributes (label or formulation changes).

Which companies could enter around the same time as Alvogen?

Answer (featured snippet style): Other ANDA filers pursuing the same RLD can face similar patent blocks from the same Orange Book estate; the practical entry window depends on the last enforceable patent and any global settlement terms tied to the RLD.

How to map competitor timelines

• Identify other ANDAs with Paragraph IV certifications on the same RLD.
• Track which asserted patents those cases target.
• Model which filers have settlements that set a de facto launch date.

What is the Orange Book status of the Novartis patents at issue in 1:13-cv-00370?

Answer (featured snippet style): The asserted patents are Orange Book-listed patents associated with the RLD and are certified in the defendant’s ANDA; Orange Book status determines which patents can be enforced against the ANDA filer during the infringement window.

Orange Book mapping framework

Analysts typically:

• Pull the RLD’s patent list.
• Match each patent to the asserted list in the complaint.
• Use expiration dates plus any pediatric extensions to determine the hard stop for launch.

How does this case compare with other Novartis generic patent litigations?

Answer (featured snippet style): Like many Novartis Paragraph IV matters, the case is designed to resolve validity and infringement of a finite subset of Orange Book patents and set a binding timeline for generic entry.

Comparison axes that change outcomes

• Patent category composition (formulation versus method-of-use).
• Whether claim construction turns on drug-specific features or general dosage mechanics.
• Whether settlement includes a defined launch date and label restrictions.

What settlement terms typically follow in cases like 1:13-cv-00370?

Answer (featured snippet style): Settlements in Hatch-Waxman cases often include agreed entry dates, covenants not to sue, and sometimes label or formulation constraints to preserve design-around positions.

Settlement clauses that affect market timing

• A launch trigger keyed to patent expiration or an agreed date.
• Stipulated dismissal with prejudice after payment terms.
• No earlier commercial marketing provisions.
• Label carve-outs tied to method-of-use claim avoidance.

Regulatory timeline: how FDA approval timing interacts with litigation

Answer (featured snippet style): FDA approval is often blocked from commercial launch by patent enforcement (in practice, via injunctions or settlement), even if FDA’s review completes.

Mechanics

• If ANDA approval occurs but launch is enjoined, the product can remain commercially “paused.”
• If approval is tied to the litigation stay and settlement, the court and settlement drive real-world entry timing.

Key takeaway table: litigation-to-entry drivers

Driver	What it means for Alvogen	What to track in docket/court docs
Asserted patent set	Defines the infringement and validity targets	Complaint, asserted claims chart, Markman orders
Claim construction	Can narrow claim scope and change infringement	Claim terms ruling dates and outcomes
Infringement ruling	Determines likelihood of injunction	Claim-by-claim infringement analysis
Validity ruling	Determines whether patents remain enforceable	Prior art references and obviousness findings
Settlement or final judgment	Sets launch date and damages exposure	Dismissal order, settlement agreement terms
Orange Book last-expiring date	Caps lawful entry without risk	Orange Book patent expiration list

Key Takeaways

• 1:13-cv-00370 is a Hatch-Waxman Paragraph IV dispute where Novartis uses Orange Book-listed patents to block or condition Alvogen’s generic entry.
• The case’s decisive business input is the last enforceable asserted patent and the court or settlement outcome that translates to lawful launch timing.
• For generic-entry risk, focus on the patent category (composition/formulation vs method-of-use), because it determines how easily Alvogen can redesign label or product attributes.

FAQs

1. How do Paragraph IV settlements typically translate into FDA launch dates?
2. Which claim types (method-of-use vs formulation) are most likely to survive invalidity challenges in Novartis Paragraph IV cases?
3. What does “at-risk” launch mean after a district court decision in Hatch-Waxman litigation?
4. How do Markman rulings shift infringement analysis in generic design-around scenarios?
5. How do Orange Book “last-to-expire” patents affect multi-filer ANDA competitive dynamics?

References

1. U.S. District Court, (Docket) Novartis Pharmaceuticals Corporation v. Alvogen Pine Brook Inc., No. 1:13-cv-00370.
2. FDA, Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations (accessed via Orange Book listings for the relevant RLD).